Monoclonal antibodies that recognize epitopes of amyloid-beta
US7772375B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 11, 2006 |
| Grant date | Aug 10, 2010 |
| Priority date | — |
| Expiry date | Aug 16, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4709
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.